1-11 of 11
Li Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)

MinKe He, YeXing Huang, ZeFeng Du, ZhiCheng Lai, Hanyue Ouyang, JingXian Shen, DongSheng Wen, QiJiong Li, YaoJun Zhang, Wei Wei, MinShan Chen, Li Xu, Anna Kan, Ming Shi
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5104–5115.
https://doi.org/10.1158/1078-0432.CCR-23-0060
Published: 15 December 2023
View article titled, Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
Open the PDF for Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC) in another window
Includes: Supplementary data
Journal Articles

An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas

Xiaofan Lu, Yann Vano, Alexandra Helleux, Xiaoping Su, Véronique Lindner, Guillaume Davidson, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Reza Elaidi, Eva Compérat, Virginie Verkarre, Chengming Sun, Christine Chevreau, Mostefa Bennamoun, Hervé Lang, Thibault Tricard, Wenxuan Cheng, Li Xu, Irwin Davidson, Fangrong Yan, Wolf Herman Fridman, Catherine Sautes-Fridman, Stéphane Oudard, Gabriel G. Malouf
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1279–1291.
https://doi.org/10.1158/1078-0432.CCR-22-2133
Published: 03 April 2023
View article titled, An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Open the PDF for An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang, Quanren Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1003–1011.
https://doi.org/10.1158/1078-0432.CCR-20-2571
Published: 15 February 2021
View article titled, Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Open the PDF for Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma

Wen Sun, Shi-Chao Li, Li Xu, Wei Zhong, Zhen-Guang Wang, Chu-zhi Pan, Jing Li, Guang-Zhi Jin, Na Ta, Wei Dong, Dan Liu, Hui Liu, Hong-Yang Wang, Jin Ding
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4302–4312.
https://doi.org/10.1158/1078-0432.CCR-19-1858
Published: 14 August 2020
View article titled, High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
Open the PDF for High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract A30: Association of pretreatment BMI with risk of head and neck cancer: A large-scale single-center study

Anshu Khanna, Eric Sturgis, Li Xu, Qingyi Wei, Guojun Li, Neil Gross
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): A30.
https://doi.org/10.1158/1557-3265.AACRAHNS19-A30
Published: 15 June 2020
View article titled, Abstract A30: Association of pretreatment BMI with risk of head and neck cancer: A large-scale single-center study
Journal Articles

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Tina Cascone, Li Xu, Heather Y. Lin, Wenbin Liu, Hai T. Tran, Yuan Liu, Kathryn Howells, Vincent Haddad, Emer Hanrahan, Monique B. Nilsson, Maria A. Cortez, Uma Giri, Humam Kadara, Babita Saigal, Yun-Yong Park, Weiyi Peng, Ju-Seog Lee, Anderson J. Ryan, Juliane M. Jüergensmeier, Roy S. Herbst, Jing Wang, Robert R. Langley, Ignacio I. Wistuba, Jack J. Lee, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5489–5501.
https://doi.org/10.1158/1078-0432.CCR-16-3216
Published: 14 September 2017
View article titled, The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Open the PDF for The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma

Jing Xu, Jing Liang, Ya-Ming Meng, Jing Yan, Xing-Juan Yu, Chao-Qun Liu, Li Xu, Shi-Mei Zhuang, Limin Zheng
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4482–4492.
https://doi.org/10.1158/1078-0432.CCR-16-2131
Published: 01 August 2017
View article titled, Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma
Open the PDF for Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou, Jin-Ji Yang, Xue-Ning Yang, Jia-Xin Lin, Hong-Hong Yan, Hao-Ran Zhai, Li-Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi-Long Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3012–3024.
https://doi.org/10.1158/1078-0432.CCR-16-2554
Published: 14 June 2017
View article titled, Potential Predictive Value of <em>TP53</em> and <em>KRAS</em> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Open the PDF for Potential Predictive Value of <em>TP53</em> and <em>KRAS</em> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2

Hui Hua, Jiao Wang, Li Xu, Yangfu Jiang
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22_Supplement): B30.
Published: 15 August 2014
View article titled, Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2
Journal Articles

Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation

Xianping Shi, Xin Chen, Xiaofen Li, Xiaoying Lan, Chong Zhao, Shouting Liu, Hongbiao Huang, Ningning Liu, Siyan Liao, Wenbin Song, Ping Zhou, Shunqing Wang, Li Xu, Xuejun Wang, Q. Ping Dou, Jinbao Liu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 151–163.
https://doi.org/10.1158/1078-0432.CCR-13-1063
Published: 05 January 2014
View article titled, Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
Open the PDF for Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation in another window
Includes: Supplementary data
Journal Articles

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjorn Straume, Lars A. Akslen, Eugene Lifshits, Lauren Averett Byers, Li Xu, Hua-kang Wu, Pasi Jänne, Susumu Kobayashi, Balazs Halmos, Daniel Tenen, Xi M. Tang, Jeffrey Engelman, Beow Yeap, Judah Folkman, Bruce E. Johnson, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3484–3494.
https://doi.org/10.1158/1078-0432.CCR-08-2904
Published: 18 May 2009
View article titled, Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
Open the PDF for Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance in another window